To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for treating inadequately controlled severe asthma with elevated blood eosinophils.
Status In progress
Process STA
ID number 1129

Provisional Schedule

Committee meeting: 1 17 April 2018
Expected publication 19 September 2018

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
03 November 2017 In progress, Appraisal in progress
03 November 2017 Invitation to participate
29 March 2017 - 28 April 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance